Fig. 1
From: Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
Activity of single agent 5-fluorouracil, oxaliplatin, SN38, and niraparib and niraparib-chemotherapy combinations in a panel of human CRC cell lines. a: 96 h proliferation assay (MTT) for niraparib, 5FU, oxaliplatin, SN38 in each of the cell lines included in the panel. b: Combination index according to the Chou-Talalay model of drug interaction at effective dose (ED) 50, ED75 and ED90. The combination between niraparib and SN38 is the more frequently synergistic across EDs (6/12 cell lines), with a combination index (CI) < 0,75